Compare NRK & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRK | XNCR |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.1M | 928.3M |
| IPO Year | N/A | 2013 |
| Metric | NRK | XNCR |
|---|---|---|
| Price | $10.18 | $12.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $22.78 |
| AVG Volume (30 Days) | 187.3K | ★ 721.7K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $150,132,000.00 |
| Revenue This Year | N/A | $18.68 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $8.95 | $6.92 |
| 52 Week High | $11.09 | $20.09 |
| Indicator | NRK | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 36.64 |
| Support Level | $10.11 | $12.50 |
| Resistance Level | $10.19 | $13.63 |
| Average True Range (ATR) | 0.05 | 0.73 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 41.67 | 8.44 |
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.